Bimekizumab Long-Term Safety and Efficacy Across the Spectrum of Axial Spondyloarthritis Over 3 Years: Results From 2 Phase III Studies

医学 不利影响 巴斯菲 入射(几何) 内科学 疾病 巴斯代人 外科 强直性脊柱炎 临床研究阶段 疾病控制 安全概况 轴性脊柱炎 葡萄膜炎 脊柱炎 临床疗效 临床试验 广谱 痹症科 物理疗法 胃肠病学 生活质量(医疗保健)
作者
Xenofon Baraliakos,Atul A. Deodhar,Désirée M F M van der Heijde,Filip E Van den Bosch,Marina Magrey,Walter P. Maksymowych,Tetsuya Tomita,Huji Xu,Jason Coarse,Chetan Prajapati,Myriam Manente,Alexander Marten,Lianne S. Gensler
出处
期刊:The Journal of Rheumatology [The Journal of Rheumatology Publishing Company Limited]
卷期号:53 (10): 1071-1082 被引量:6
标识
DOI:10.3899/jrheum.2026-0113
摘要

Objective The safety and efficacy of bimekizumab, a dual interleukin (IL)-17A and IL-17F inhibitor, have been demonstrated over 2 years across the full disease spectrum of axial spondyloarthritis (axSpA). We report long-term safety and efficacy of bimekizumab over 3 years. Methods Patients who completed week 52 of the phase III BE MOBILE 1 (nonradiographic axial spondyloarthritis [axSpA]; ClinicalTrials.gov : NCT03928704 ) and BE MOBILE 2 (radiographic axSpA; NCT03928743 ) studies were eligible to enter an ongoing open-label extension (OLE; NCT04436640 ) and continue receiving subcutaneous bimekizumab 160 mg every 4 weeks. Safety outcomes for patients who received ≥ 1 dose of bimekizumab and efficacy outcomes for all randomized patients are reported over 3 years (164 weeks [112-week OLE]). Results During the overall safety period, 90.4% (519/574) of patients had ≥ 1 treatment-emergent adverse event. Fungal infection exposure-adjusted incidence rate (EAIR) per 100 patient-years (PY) was 9.4 (the majority were Candida infections, 5.3/100 PY; most infections were mild or moderate, none were serious or systemic). The EAIRs per 100 PY for inflammatory bowel disease and uveitis were 0.5 and 1.5, respectively. No major adverse cardiovascular events or deaths occurred. EAIRs, including those for Candida infections, were generally lowest in the third year. The efficacy of bimekizumab observed through 2 years was sustained through week 164. At week 164, 57.0% of patients achieved an Axial Spondyloarthritis Disease Activity Score (ASDAS) indicating low disease activity (< 2.1), including 28.7% who achieved ASDAS inactive disease (< 1.3). Bimekizumab treatment also led to sustained improvements in Bath Ankylosing Spondylitis Functional Index (BASFI) and health-related quality of life scores and sustained control of magnetic resonance imaging (MRI) inflammation through week 164, with 59.4% and 77.8% of patients achieving Spondyloarthritis Research Consortium of Canada (SPARCC) sacroiliac joint scores < 2 and Berlin spine scores ≤ 2, respectively. Conclusion Bimekizumab was well tolerated over 3 years, with no new safety signals observed. Across the full disease spectrum of axSpA, patients demonstrated sustained clinical efficacy and inflammation control over 3 years.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
焦虑的牛马关注了科研通微信公众号
刚刚
田様的应助被通过采纳,获得10
1秒前
lejunia发布了新的文献求助10
1秒前
u0u0uu0发布了新的文献求助10
2秒前
kkkkkkkk完成签到,获得积分10
2秒前
西北发布了新的文献求助10
2秒前
3秒前
4秒前
4秒前
4秒前
4秒前
大模型的应助被文静的飞柏采纳,获得10
4秒前
5秒前
5秒前
5秒前
6秒前
隐形曼青的应助被科研通管家采纳,获得10
6秒前
369ninja发布了新的文献求助10
6秒前
NexusExplorer的应助被科研通管家采纳,获得10
6秒前
852的应助被科研通管家采纳,获得10
6秒前
Jasper的应助被科研通管家采纳,获得10
6秒前
6秒前
醋溜滑板完成签到,获得积分10
6秒前
Ava的应助被科研通管家采纳,获得10
6秒前
充电宝的应助被科研通管家采纳,获得30
7秒前
7秒前
田様的应助被科研通管家采纳,获得10
7秒前
ay的应助被XIN采纳,获得10
7秒前
CipherSage的应助被科研通管家采纳,获得10
7秒前
华仔的应助被科研通管家采纳,获得30
7秒前
星辰大海的应助被科研通管家采纳,获得10
7秒前
秋风的应助被科研通管家采纳,获得20
7秒前
传奇3的应助被科研通管家采纳,获得10
7秒前
情怀的应助被科研通管家采纳,获得10
8秒前
完美世界的应助被科研通管家采纳,获得10
8秒前
shangguang的应助被科研通管家采纳,获得50
8秒前
8秒前
JamesPei的应助被科研通管家采纳,获得10
8秒前
勤恳兔子的应助被科研通管家采纳,获得10
8秒前
所所的应助被科研通管家采纳,获得10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181279
求助须知:如何正确求助?哪些是违规求助? 9571198
关于积分的说明 21817073
捐赠科研通 7777612
什么是DOI,文献DOI怎么找? 3433454
关于科研通互助平台的介绍 2557692
邀请新用户注册赠送积分活动 2479519